AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32073648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib monotherapy
Number of subjects: 78
Study 35017288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Mobilization (CM)
Number of subjects: 12
Study 35017288 — intervention group
Group type: COMPARATOR
Intervention: Traditional Treatment (TM)
Number of subjects: 12
Study 32366314 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management intervention package
Number of subjects: 110
Study 32366314 — intervention group
Group type: COMPARATOR
Intervention: Standard of care plus asthma education (Control)
Number of subjects: 110
Study 35556023 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Housing (EH) conditions, implemented for 2 hrs/day, 5 days/week for 4 weeks starting 1 week after surgery.
Number of subjects: 0
Study 35556023 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Housing (EH) conditions
Number of subjects: 0
Study 35556023 — intervention group
Group type: COMPARATOR
Intervention: Standard Housing (SH) conditions
Number of subjects: 0
Study 32762995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 463
Study 32762995 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 463
Study 32762995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 463
Study 32762995 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-fitting models for EQ-5D and EQ-5D V
Number of subjects: 463
Study 32762995 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-fitting model for VFQ-UI
Number of subjects: 463
Study 35006497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's Own Milk (OMOM)
Number of subjects: 133
Study 35006497 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 133
Study 36122589 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHMs) in fifty‐millesimal (LM) potencies
Number of subjects: 62
Study 36122589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 34334431 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 3 U/kg/OT
Number of subjects: 235
Study 34334431 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 6 U/kg/OT
Number of subjects: 235
Study 34334431 — intervention group
Group type: COMPARATOR
Intervention: placebo/OT
Number of subjects: 235
Study 34334431 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (3 and 6 U/kg)
Number of subjects: 235
Study 34334431 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 235
Study 32132105 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher abundance of CD8+CD45RO‐CCR7‐CD57+ cells
Number of subjects: 38
Study 32132105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower abundance of CD14+CD33+CD85j+ cells
Number of subjects: 38
Study 32132105 — intervention group
Group type: COMPARATOR
Intervention: Lower abundance of CD8+CD45RO‐CCR7‐CD57+ cells
Number of subjects: 38
Study 32132105 — intervention group
Group type: COMPARATOR
Intervention: Higher abundance of CD14+CD33+CD85j+ cells
Number of subjects: 38
Study 34316017 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin in addition to intensive chemotherapy
Number of subjects: 452
Study 34316017 — intervention group
Group type: EXPERIMENTAL
Intervention: JMDsole
Number of subjects: 452
Study 34316017 — intervention group
Group type: EXPERIMENTAL
Intervention: JMD/TKD1
Number of subjects: 452
Study 34316017 — intervention group
Group type: EXPERIMENTAL
Intervention: TKD1sole
Number of subjects: 452
Study 34316017 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 452
Study 34521933 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 0
Study 35697428 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Coach application (AC-app)
Number of subjects: 32
Study 35697428 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 32
Study 32826637 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy for 3 min
Number of subjects: 11
Study 32826637 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension exercise (KEX) at 25% of one-repetition maximum for 3 min
Number of subjects: 11
Study 32826637 — intervention group
Group type: COMPARATOR
Intervention: Both WBV and KEX
Number of subjects: 11
Study 35149574 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of progestogen only pill (POP) with emergency contraception (EC) from pharmacies as routine practice
Number of subjects: 599
Study 35149574 — intervention group
Group type: COMPARATOR
Intervention: Rapid-access to sexual and reproductive health (SRH) services
Number of subjects: 599
Study 32037531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postplacental PPIUD (≤10 minutes)
Number of subjects: 560
Study 32037531 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PPIUD (>10 minutes)
Number of subjects: 560
Study 34280069 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming using Nintendo Wii Fit™ for 8 weeks
Number of subjects: 0
Study 34280069 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 8 weeks
Number of subjects: 0
Study 34169195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cycling (IDC)
Number of subjects: 109
Study 34169195 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 109
Study 36206498 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab 240 mg plus chemotherapy
Number of subjects: 465
Study 36206498 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 465
Study 36206498 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab 240 mg plus chemotherapy with high tumor mutational burden
Number of subjects: 465
Study 36206498 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy with high tumor mutational burden
Number of subjects: 465
Study 36206498 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab 240 mg plus chemotherapy with mutations in the focal adhesion-PI3K-Akt signaling pathway
Number of subjects: 465
Study 33888749 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on plain CT images
Number of subjects: 134
Study 33888749 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 134
Study 36075242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg daily)
Number of subjects: 123
Study 36075242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 36075242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 123
Study 33949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T1WI
Number of subjects: 103
Study 33949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T1WI + T2WI-FS
Number of subjects: 103
Study 33949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T2WI-FS
Number of subjects: 103
Study 33949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram based on T1WI
Number of subjects: 103
Study 33949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram based on T2WI-FS
Number of subjects: 103
Study 33949727 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical radiomics nomogram based on T1WI + T2WI-FS
Number of subjects: 103
Study 36296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + high-protein diet (1.2-1.5 g/kg)
Number of subjects: 61
Study 36296958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + high-protein and omega-3-enriched diet (2.2 g/day)
Number of subjects: 61
Study 36296958 — intervention group
Group type: COMPARATOR
Intervention: Exercise (3x/week)
Number of subjects: 61
Study 33649056 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (CMFO)
Number of subjects: 0
Study 33649056 — intervention group
Group type: COMPARATOR
Intervention: Placebo flat cushioning insoles
Number of subjects: 0
Study 32941530 — intervention group
Group type: EXPERIMENTAL
Intervention: 3PS programme (n = 27)
Number of subjects: 54
Study 32941530 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 27)
Number of subjects: 54
Study 35032704 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially automated driving conditions (L2) with non-driving related tasks (NDRT)
Number of subjects: 37
Study 35032704 — intervention group
Group type: COMPARATOR
Intervention: Partially automated driving conditions (L2) without NDRT
Number of subjects: 37
Study 35032704 — intervention group
Group type: COMPARATOR
Intervention: Manual driving conditions
Number of subjects: 37
Study 32722819 — intervention group
Group type: EXPERIMENTAL
Intervention: GCK-MODY
Number of subjects: 162
Study 32722819 — intervention group
Group type: EXPERIMENTAL
Intervention: HNF-MODY
Number of subjects: 162
Study 34091954 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 27
Study 34091954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 35235726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 1490
Study 35235726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1490
Study 33462825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose tablet (50 mg and 100 mg) administered by chewing
Number of subjects: 24
Study 33462825 — intervention group
Group type: COMPARATOR
Intervention: Acarbose tablet (50 mg and 100 mg) administered by swallowing
Number of subjects: 24
Study 36186541 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching with Four Quadrant Model of Facilitated Learning (OPC+4QM)
Number of subjects: 0
Study 36186541 — intervention group
Group type: COMPARATOR
Intervention: Occupational Performance Coaching alone (OPC)
Number of subjects: 0
Study 33428347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 86
Study 33428347 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 86
Study 34648425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 118
Study 34648425 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP)
Number of subjects: 118
Study 34648425 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring followed by CBT-I concurrent with PAP
Number of subjects: 118
Study 34648425 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring followed by PAP only
Number of subjects: 118
Study 33558678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 22
Study 33558678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32019736 — intervention group
Group type: EXPERIMENTAL
Intervention: PRBCs with Hb content ≥50 g (Group I, n = 80)
Number of subjects: 160
Study 32019736 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected PRBCs (Group II, n = 80)
Number of subjects: 160
Study 35598427 — intervention group
Group type: EXPERIMENTAL
Intervention: Against Stigma Program (60-minute weekly sessions for 6 weeks)
Number of subjects: 70
Study 35598427 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control group)
Number of subjects: 70
Study 34747087 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (Hb transfusion threshold <75 g/L)
Number of subjects: 5092
Study 34747087 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (Hb <95 g/L for operating room or ICU; <85 g/L for ward)
Number of subjects: 5092
Study 34747087 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 5092
Study 32828873 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-Scope Clip (OTSC)
Number of subjects: 53
Study 32828873 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic hemostasis (with hemoclips or multipolar electrocoagulation - MPEC)
Number of subjects: 53
Study 32379240 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 10
Study 32379240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 33237938 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile of AHEI-P score (39.59-56.58)
Number of subjects: 174
Study 33237938 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of AHEI-P score (<39.59)
Number of subjects: 174
Study 35697429 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 48
Study 35697429 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 48
Study 33148667 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin at 45 mg/m2
Number of subjects: 16
Study 33148667 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin at 90 mg/m2
Number of subjects: 16
Study 33148667 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin at 120 mg/m2
Number of subjects: 16
Study 33148667 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin (all doses)
Number of subjects: 16
Study 33148667 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC oxaliplatin (two procedures)
Number of subjects: 16
Study 32526688 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention (3 sessions, 60-90 minutes each)
Number of subjects: 80
Study 32526688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 34605077 — intervention group
Group type: EXPERIMENTAL
Intervention: FREMS + usual care
Number of subjects: 25
Study 34605077 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study 34331985 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36 °C
Number of subjects: 57
Study 34331985 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33 °C
Number of subjects: 57
Study 34331985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low rSO2 levels at 24 hours of TTM
Number of subjects: 57
Study 36252936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0
Study 36252936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health application (mHealth) behavioral management
Number of subjects: 0
Study 36252936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and mHealth app
Number of subjects: 0
Study 36252936 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study 34972100 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated microfinance/livelihood and community‐based rehabilitation (IMCBR) program
Number of subjects: 210
Study 34972100 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐based rehabilitation (CBR) alone
Number of subjects: 210
Study 34972100 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (no intervention)
Number of subjects: 210
Study 33165566 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV3)
Number of subjects: 24396
Study 33165566 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Poliovirus Vaccine (IPV)
Number of subjects: 24396
Study 33138797 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression quantified using the NanoString nCounter Immunology Panel
Number of subjects: 55
Study 33138797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models based on random Forest using DEGs
Number of subjects: 55
Study 33138797 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive models in edgeR for pre- and post-treatment groups
Number of subjects: 55
Study 33138797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression model-based survival analysis
Number of subjects: 55
Study 33138797 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization test for prediction models
Number of subjects: 55
Study 34281788 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-time micro-osteoperforation (MOP)
Number of subjects: 16
Study 34281788 — intervention group
Group type: COMPARATOR
Intervention: One-time micro-osteoperforation (MOP)
Number of subjects: 16
Study 32035552 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg bimekizumab
Number of subjects: 206
Study 32035552 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg bimekizumab
Number of subjects: 206
Study 32035552 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg bimekizumab with a one-off 320 mg loading dose
Number of subjects: 206
Study 32035552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 32035552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (all doses combined)
Number of subjects: 206
Study 35770546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fateh massage
Number of subjects: 84
Study 35770546 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 84
Study 35770546 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 84
Study 33558346 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 0
Study 33558346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 0
Study 33558346 — intervention group
Group type: EXPERIMENTAL
Intervention: Christian prayer
Number of subjects: 0
Study 33558346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific strategy)
Number of subjects: 0
Study 36099136 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous and metachronous other primary cancer
Number of subjects: 244
Study 36099136 — intervention group
Group type: COMPARATOR
Intervention: No synchronous and metachronous other primary cancer
Number of subjects: 244
Study 33284116 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based diet tracking plus feedback on DASH adherence via text message
Number of subjects: 59
Study 33284116 — intervention group
Group type: COMPARATOR
Intervention: App-based diet tracking (active comparator)
Number of subjects: 59
Study 35607975 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily written updates on the satisfaction and psychologic symptoms of families of ICU patients
Number of subjects: 252
Study 33821928 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Contact Cognitive Behavioral Therapy (MC-CBT)
Number of subjects: 145
Study 33821928 — intervention group
Group type: COMPARATOR
Intervention: Standard Cognitive Behavioral Therapy (S-CBT)
Number of subjects: 145
Study 33821928 — intervention group
Group type: COMPARATOR
Intervention: Education/Support (EDU)
Number of subjects: 145
Study 33357641 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg twice-daily
Number of subjects: 637
Study 33357641 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg twice-daily
Number of subjects: 637
Study 34473295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily for 24 months
Number of subjects: 0
Study 34473295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34264296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Atropine and Patching Therapy (CAPT)
Number of subjects: 108
Study 34264296 — intervention group
Group type: COMPARATOR
Intervention: Patching alone
Number of subjects: 108
Study 32433510 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle‐PAP
Number of subjects: 232
Study 32433510 — intervention group
Group type: COMPARATOR
Intervention: FP‐CPAP
Number of subjects: 232
Study 34775781 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Number of subjects: 618
Study 34286560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg plus nutritional supplement (Panax ginseng, Moringa Oleifera, Rutin) once daily for 3 months
Number of subjects: 86
Study 34286560 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg plus placebo once daily for 3 months
Number of subjects: 86
Study 34286560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 86
Study 32668113 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.3% cream
Number of subjects: 331
Study 32668113 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.15% cream
Number of subjects: 331
Study 32668113 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 331
Study 32668113 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.3% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Number of subjects: 331
Study 32668113 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.15% cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Number of subjects: 331
Study 32668113 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (for patients with baseline intertriginous psoriasis of at least mild severity)
Number of subjects: 331
Study 34420102 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 81
Study 34420102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 81
Study 33786980 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Sealing Drainage (VSD)
Number of subjects: 130
Study 33786980 — intervention group
Group type: COMPARATOR
Intervention: Routine Dressing Change (RDC)
Number of subjects: 130
Study 32745165 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Access
Number of subjects: 2119
Study 32745165 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Access
Number of subjects: 2119
Study 35093794 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating three benefits of a policy
Number of subjects: 4616
Study 35093794 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating one benefit of a policy
Number of subjects: 4616
Study 32885526 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meal-replacement (pMR) hypocaloric diet for 12 weeks
Number of subjects: 122
Study 32572154 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote digital pathology system from a non-CLIA certified facility
Number of subjects: 12
Study 32572154 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote digital pathology system
Number of subjects: 12